179 related articles for article (PubMed ID: 19321281)
21. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Hollebecque A; Cattan S; Romano O; Sergent G; Mourad A; Louvet A; Dharancy S; Boleslawski E; Truant S; Pruvot FR; Hebbar M; Ernst O; Mathurin P
Aliment Pharmacol Ther; 2011 Nov; 34(10):1193-201. PubMed ID: 21958438
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
[TBL] [Abstract][Full Text] [Related]
23. Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
Frenette CT; Frederick RT; Gish RG
J Clin Gastroenterol; 2011 Sep; 45(8):733-7. PubMed ID: 20930642
[TBL] [Abstract][Full Text] [Related]
24. Platelet count less than SHARP: what does a case series reveal?
Saif MW
Expert Opin Drug Saf; 2010 Jan; 9(1):1-8. PubMed ID: 20001607
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma.
Liang CP; Yang CS; Shen JL; Chen YJ
Br J Dermatol; 2011 Aug; 165(2):443-5. PubMed ID: 21495998
[No Abstract] [Full Text] [Related]
26. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Kane RC; Farrell AT; Madabushi R; Booth B; Chattopadhyay S; Sridhara R; Justice R; Pazdur R
Oncologist; 2009 Jan; 14(1):95-100. PubMed ID: 19144678
[TBL] [Abstract][Full Text] [Related]
28. Sorafenib-induced bilateral osteonecrosis of femoral heads.
Guillet M; Walter T; Scoazec JY; Vial T; Lombard-Bohas C; Dumortier J
J Clin Oncol; 2010 Jan; 28(2):e14. PubMed ID: 19884542
[No Abstract] [Full Text] [Related]
29. Evaluation of multiple targeted agents as potential therapies for hepatocellular carcinoma (HCC). Foreword.
Kummar S
Curr Probl Cancer; 2010; 34(2):130. PubMed ID: 20417352
[No Abstract] [Full Text] [Related]
30. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
31. Hyperkeratosis of nipple skin during sorafenib treatment.
Frigerio M; Santi V; Di Micoli A; Trevisani F
Dig Liver Dis; 2009 Aug; 41(8):611. PubMed ID: 19303375
[No Abstract] [Full Text] [Related]
32. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
33. Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
Morimoto M; Numata K; Moriya S; Kondo M; Nozaki A; Morioka Y; Maeda S; Tanaka K
Anticancer Res; 2012 Feb; 32(2):619-23. PubMed ID: 22287754
[TBL] [Abstract][Full Text] [Related]
34. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
Cabibbo G; Rolle E; De Giorgio M; Genco C; Pressiani T; Spada F; Sacco R;
Expert Rev Anticancer Ther; 2011 Dec; 11(12):1807-16. PubMed ID: 22049974
[TBL] [Abstract][Full Text] [Related]
35. Sorafenib: new indication. For some patients with liver cancer.
Prescrire Int; 2009 Apr; 18(100):59. PubMed ID: 19585718
[TBL] [Abstract][Full Text] [Related]
36. Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Lynch MC; Straub R; Adams DR
J Drugs Dermatol; 2011 Mar; 10(3):308-10. PubMed ID: 21369650
[TBL] [Abstract][Full Text] [Related]
37. Hyperkeratotic eczema of the nipple and areola associated with sorafenib treatment.
Tougeron D; Wierzbicka-Hainaut E; Osdoit S; Chagneau-Derrode C; Yacoub M; Silvain C
Eur J Dermatol; 2010; 20(6):854-6. PubMed ID: 20956109
[No Abstract] [Full Text] [Related]
38. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
Mancuso A; Airoldi A; Vigano R; Pinzello G
Dig Liver Dis; 2011 Sep; 43(9):754. PubMed ID: 21641889
[No Abstract] [Full Text] [Related]
39. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
40. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
